Streptokinase: From Natural to Recombinant to Next-generation Drugs

CSIR has developed a portfolio of Streptokinase technology, a vital, life-saver injectable protein cardiovascular drug. Natural and recombinant streptokinase developed by CSIR is already in the market benefiting the people of the country. CSIR has also designed a state-of-the-art clot buster protein (Clot Specific Streptokinase) which shows strong promise as a ‘clot-specific’ thrombolytic drug, has received clearance from DCGI and is currently in Phase II clinical trials.